Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Chattem supplement claims

This article was originally published in The Tan Sheet

Executive Summary

For Echinex and Propalmex dietary supplements cited as unapproved new drug claims by FDA in April 20 warning letter. Claims for Echinex, an echinacea supplement, include that it supports or boosts "the body's natural resistance against infection" and "viruses and bacteria won't slow you down." For Propalmex, a saw palmetto product, statements include: "Most men over 45 experience a gradual increase in the prostate size at some time during or after middle age. Due to the fact that the prostate surrounds the urinary tract, an enlarged prostate can lead to an obstruction of urinary flow...can mean discomfort in urination or increased night-time urination," and "Propalmex can help to support prostate health and promote free urinary flow." The company, which is preparing a response, did not previously receive a "courtesy" letter on the claims. Chattem acquired the supplement products in June 1997 as part of its Sunsource purchase
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

PS089765

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel